
Oil Is the New Gold


| Price and Volume | |
|---|---|
| Recent Price | 3.84 |
| 52 Week High | 16.43 |
| 52 Week Low | 3.66 |
| Avg. Daily Vol. (Mil) | 0.03 |
| Beta (3 year) | 0.99 |
| Share Related Items | |
| Mkt Cap (Mil) | 70.97 |
| Shares Out (Mil) | 18.48 |
| Float (Mil) | 15.69 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 12.00 |
| Current Ratio | 12.40 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 0.00 |
| Price/Book | 2.49 |
| Price/Cash Flow | -3.80 |
| Per Share Data | |
| Earnings | -1.40 |
| Sales | 0.00 |
| Book Value | 1.54 |
| Cash Flow | -1.01 |
| Business Summary | |
|---|---|
| Medgenics Inc is a medical technology and therapeutics company engaged in providing sustained protein therapies to treat chronic diseases and conditions. | |
| General Information | |
| 555 California Street
Suite 365 San Francisco, CA 94104 |
|
| www.medgenics.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 34 | |
| CEO: Andrew Leonard Pearlman | |
| Short Interest | |
| Current Month (Mil) | 0.37 |
| Previous Month (Mil) | 0.38 |
| Short Interest Ratio (Days) | 15.20 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -55.70 |
| Return on Investments | -65.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |